Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.
| Website | http://www.invitris.com |
| Employees | 20 (12 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
PHP
+4 more
(view full list)
|
| Industry | Biotechnology |
| Keywords | Biomanufacturing, Synthetic Biology, Protein Engineering, Biotechnology Platform, Protein Design, Drug Discovery, Biopharmaceutical, Therapeutic Proteins, Protein Therapeutics, Biotechnology, Pharmaceutical Development, Precision Medicine, Molecular Engineering, Biotechnology Solutions, Life Sciences, Pharmaceutical Research, Biologics, Drug Development, Genetic Engineering |
| Competitors | Thermo Fisher Scientific, Illumina, Agilent Technologies, Bio-Rad Laboratories, PerkinElmer, Inc., Roche, QIAGEN, Merck Group, MilliporeSigma, ThermoGenesis Corp. +49 more (view full list) |
Looking for a particular Invitris employee's phone or email?
Kilian Vogele is the CTO and Co-Founder of Invitris.
12 people are employed at Invitris.
Invitris is based in Dover, Delaware.